期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

突出综合实力开创肺癌诊治新时代

New era for treatment of lung cancers through emphasis of comprehensive skills
原文传递
导出
作者 白春学
机构地区 复旦大学附属中山医院呼吸科
出处 《中华肺部疾病杂志（电子版）》 CAS 2008年第1期71-73,共3页 Chinese Journal of Lung Diseases(Electronic Edition)
关键词 肺癌 诊断 综合治疗
分类号 R734.2 [医药卫生—肿瘤] R563.8 [医药卫生—呼吸系统]
  • 相关文献

参考文献7

  • 1白春学,张新.肺癌的治疗现状[J].中华结核和呼吸杂志,2006,29(3):146-148. 被引量：61
  • 2Fry W A,Menck H R,Winchester D P,et al.The national cancer data base report on lung cancer[].Cancer.1996
  • 3Fong K,Sekido Y,Gazdar JD,et al.Lung cancer 9:Molecular biology of lung cancer clinical implications[].Thorax.2003
  • 4Lynch T J,Bell D W,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[].New England Journal of Homeopathy.2004
  • 5Zhang M,Zhang X,Bai CX,et al.Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells[].Acta Pharmacological Sinica.2004
  • 6Martini N,Rusch VW,Bains MS,et al.Factors influencing ten-year survival in resected stages Ⅰ to Ⅲ a non-small cell lung cancer[].Journal of Thoracic and Cardiovascular Surgery.1999
  • 7Thomas RK,Weir B,Meyerson M.Genomic approaches to lungcancer[].Clinical Cancer Research.2006

二级参考文献25

  • 1张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量：31
  • 2Baggstrom M,Socinski MA,Hensing T,et al.Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage ⅢB/Ⅳ non-small cell lung cancer (NSCLC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2002,21:306a.
  • 3Scagliotti GV,De Marinis F,Rinaldi M,et al.Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer.J Clin Oncol,2002,20:4285-4291.
  • 4Delbaldo C.Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC):a meta-analysis of the lietrature.Proc Am Soc Clin Oncol,2003,22:623.
  • 5Baggstrom M,Socinski MA,Hensing T,et al.Addressing the optimal number of cytotoxic agents in stage ⅢB/Ⅳ non-small cell lung cancer (NSLCC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2003,21:306.
  • 6Tiseo M,Boni L,Ardizzoni A.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:does cisplatin versus carboplatin make a difference? J Clin Oncol,2005,23:6276-6277.
  • 7Fossella F,Devore R,Kerr R,et al.Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol,2000,18:2354-2360.
  • 8Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597.
  • 9Pfister DG,Johnson DH,Azzoli GG,et al.American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline:update 2003.J Clin Oncol,2004,22:330-353.
  • 10Winton TL,Livingston R,Johnson D,et al.A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10.J Clin Oncol,2004,22 Suppl 14:7018.

共引文献60

中华肺部疾病杂志（电子版）
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部